Search Advanced

AIMS Medical Science

2023, Volume 10, Issue 2: 118-129. doi: 10.3934/medsci.2023010
Previous Article Next Article
Protocol Topical Sections

Hydroxyurea and pyridostigmine repurposed for treating Covid-19 multi-systems dysfunctions

  • 1.
    PhD, Associate Professor & Graduate Program Coordinator, Winston-Salem State University, School of Health Sciences, Winston-Salem, NC 27110, USA
  • 2.
    MD, Internist, Independent, Greensboro, NC 27408, USA
  • 3.
    MD, Internist (Retired), Greensboro, NC 27455, USA
  • 4.
    PharmD, Independent, Greensboro, NC 27406 USA
  • Received: 03 October 2022 Revised: 06 April 2023 Accepted: 23 April 2023 Published: 28 April 2023

  • Early in the COVID-19 pandemic, medical care providers at an acute illness hospital received increasing numbers of post-acute advanced COVID-19 patients from referring hospitals where they were showing no signs of improvement after receiving treatments from standard Emergency Use Authorization (EUA)-type protocols. The care providers turned to repurposing medications to treat these patients and added hydroxyurea, a medication commonly used for treating sickle cell anemia, to the hospital's COVID-19 treatment protocol and began to see notable clinical improvements. As the pandemic continued and new concerns arose concerning COVID-19 complications, those same care providers again turned to repurposing drugs. Focusing on the neuromuscular effects seen in COVID-19 patients, care providers turned to medications used to treat chronic neuromuscular conditions. Post-acute advanced Covid-19 patients initially received an abbreviated course of hydroxyurea followed by titrated doses of pyridostigmine. Positive responses were noted with cognition, diminished oxygen demands, progressive decrease in ventilator support, improved swallowing, and mobility. The authors suggest repurposed drugs could have great utility for treating COVID-19. It is recommended larger, COVID-19 clinical trials be completed to include hydroxyurea and pyridostigmine for validating the outcomes and clinical observations seen in these presented cases.

    Citation: Melissa R. Bowman Foster, Ali Atef Hijazi, Raymond C. Sullivan, Rebecca Opoku. Hydroxyurea and pyridostigmine repurposed for treating Covid-19 multi-systems dysfunctions[J]. AIMS Medical Science, 2023, 10(2): 118-129. doi: 10.3934/medsci.2023010

    Related Papers:

  • Early in the COVID-19 pandemic, medical care providers at an acute illness hospital received increasing numbers of post-acute advanced COVID-19 patients from referring hospitals where they were showing no signs of improvement after receiving treatments from standard Emergency Use Authorization (EUA)-type protocols. The care providers turned to repurposing medications to treat these patients and added hydroxyurea, a medication commonly used for treating sickle cell anemia, to the hospital's COVID-19 treatment protocol and began to see notable clinical improvements. As the pandemic continued and new concerns arose concerning COVID-19 complications, those same care providers again turned to repurposing drugs. Focusing on the neuromuscular effects seen in COVID-19 patients, care providers turned to medications used to treat chronic neuromuscular conditions. Post-acute advanced Covid-19 patients initially received an abbreviated course of hydroxyurea followed by titrated doses of pyridostigmine. Positive responses were noted with cognition, diminished oxygen demands, progressive decrease in ventilator support, improved swallowing, and mobility. The authors suggest repurposed drugs could have great utility for treating COVID-19. It is recommended larger, COVID-19 clinical trials be completed to include hydroxyurea and pyridostigmine for validating the outcomes and clinical observations seen in these presented cases.


    加载中

    Acknowledgments


    The authors would like to express immense gratitude to Maryna Skok D. Sci at the Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine in Kyiv for her invaluable contributions and continued dedication to the field of research. Her extensive research with α7nicotinic acetylcholine receptors have greatly contributed to our appreciation of patient clinical outcomes and given us more validation for continued efforts to share important concepts related to multi systems pathophysiologies with COVID-19.
    The authors would also like to acknowledge Anupama Matcha MD, MPH, Farouque Khan MD, Chun Li NP, Ms. Priya Varghese NP, David Best MD, and Weston Saunders MD for their amazing contribution and dedication to helping critically ill patients with repurposed drugs, which greatly contributed to the possibility of this article.

    Conflict of interest


    The authors declare no conflict of interest.

    [1] Asselah T, Durantel D, Pasmant E, et al. (2021) COVID-19: discovery, diagnostics, and drug development. J Hepatol 74: 168-184. https://doi.org/10.1016/j.jhep.2020.09.031
    [2] Huarcaya WV, Monzón JAM, Saldaña EON, et al. (2022) Impact of COVID-19 on mortality in Peru using triangulation of multiple data sources. Rev Panam Salud Publica 46: e53. https://doi.org/10.26633/RPSP.2022.53 (Article in Spanish)
    [3] Pinilla-Roncancio M, Caicedo NR (2022) Data collection and inclusion of the population with disabilities during the COVID-19 pandemic in Latin America and the Caribbean. Rev Panam Salud Publica 46: e44. https://doi.org/10.26633/RPSP.2022.44 (Article in Spanish)
    [4] Schonhaut L, Costa-Roldan I, Oppenheimer I, et al. (2022) Scientific publication speed and retractions of COVID-19 pandemic original articles. Rev Panam Salud Publica 46: e25. https://doi.org/10.26633/RPSP.2022.25
    [5] Eslava-Schmalbach J, Rosero EB, Garzón-Orjuela N (2021) Global control of COVID-19: good vaccines may not suffice. Rev Panam Salud Publica 45: e148. https://doi.org/10.26633/RPSP.2021.148
    [6] Behera BK, Radhakrishnan RV, Mohanty CR, et al. (2021) COVID-19 pandemic and its impact on peer review speed of anesthesiology journals: an observational study. J Anaesthesiol Clin Pharmacol 37: 57-62. https://doi.org/10.4103/joacp.JOACP_652_20
    [7] Duan K, Liu B, Li C, et al. (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 117: 9490-9496. https://doi.org/10.1073/pnas.2004168117
    [8] Jorda A, Kussmann M, Kolenchery N, et al. (2022) Convalescent plasma treatment in patients with Covid-19: a systematic review and meta-analysis. Front Immunol 13: 817829. https://doi.org/10.3389/fimmu.2022.817829
    [9] Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. (2021) Early convalescent plasma for high-risk outpatients with COVID-19. N Engl J Med 385: 1951-1960. https://doi.org/10.1056/NEJMoa2103784
    [10] Beigel JH, Tomashek KM, Dodd LE, et al. (2020) Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383: 1813-1826. https://doi.org/10.1056/NEJMoa2007764
    [11] Bansal V, Mahapure KS, Bhurwal A, et al. (2021) Mortality benefit of remdesivir in COVID-19: a systematic review and meta-analysis. Front Med 7: 606429. https://doi.org/10.3389/fmed.2020.606429
    [12] Lim SCL, Hor CP, Tay KH, et al. (2022) Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial. JAMA Intern Med 182: 426-435. https://doi.org/10.1001/jamainternmed.2022.0189
    [13] Foster MRB, Hijazi AA, Opoku R, et al. (2021) The use of hydroxyurea in the treatment of COVID-19. J Crit Care Med 7: 312-317. https://doi.org/10.2478/jccm-2021-0019
    [14] Cassiani SHDB, Dias BM (2021) Lessons learned from the COVID-19 pandemic: why we need to invest in advanced practice nurses. Rev Panam Salud Publica 45: e92. https://doi.org/10.26633/RPSP.2021.92
    [15] Disser NP, De Micheli AJ, Schonk MM, et al. (2020) Musculoskeletal consequences of COVID-19. J Bone Joint Surg Am 102: 1197-1204. https://doi.org/10.2106/JBJS.20.00847
    [16] Hasan LK, Deadwiler B, Haratian A, et al. (2021) Effects of COVID-19 on the musculoskeletal system: clinician's guide. Orthop Res Rev 13: 141-150. https://doi.org/10.2147/ORR.S321884
    [17] Saltis LM, Martin BR, Traeger SM, et al. (1993) Continuous infusion of pyridostigmine in the management of myasthenic crisis. Crit Care Med 21: 938-940. https://doi.org/10.1097/00003246-199306000-00025
    [18] Juel VC, Massey JM (2007) Myasthenia gravis. Orphanet J Rare Dis 2: 44. https://doi.org/10.1186/1750-1172-2-44
    [19] Skolka M, Lamb CJ, Rubin DI, et al. (2022) Electrodiagnostic characteristics suggestive of muscle-specific kinase myasthenia gravis. Neurol Clin Pract 12: 211-217. https://doi.org/10.1212/CPJ.0000000000001166
    [20] Andersen JB, Engeland A, Owe JF, et al. (2010) Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 17: 1445-1450. https://doi.org/10.1111/j.1468-1331.2010.03089.x
    [21] Gergalova G, Lykhmus O, Kalashnyk O, et al. (2012) Mitochondria express α7 nicotinic acetylcholine receptors to regulate Ca2+ accumulation and cytochrome c release: study on isolated mitochondria. PLoS One 7: e31361. https://doi.org/10.1371/journal.pone.0031361
    [22] Richtsfeld M, Yasuhara S, Fink H, et al. (2013) Prolonged administration of pyridostigmine impairs neuromuscular function with and without down-regulation of acetylcholine receptors. Anesthesiology 119: 412-421. https://doi.org/10.1097/ALN.0b013e318291c02e
    [23] Hatzimouratidis K (2006) Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging 1: 403-414. https://doi.org/10.2147/ciia.2006.1.4.403
    [24] Gns HS, Saraswathy GR, Murahari M, et al. (2019) An update on drug repurposing: re-written saga of the drug's fate. Biomed Pharmacother 110: 700-716. https://doi.org/10.1016/j.biopha.2018.11.127
    [25] Suh J, Amato AA (2021) Neuromuscular complications of coronavirus disease-19. Curr Opin Neurol 34: 669-674. https://doi.org/10.1097/WCO.0000000000000970
    [26] Tseng YH, Chen TH (2021) Care for patients with neuromuscular disorders in the COVID-19 pandemic era. Front Neurol 12: 607790. https://doi.org/10.3389/fneur.2021.607790
    [27] Pisella LI, Fernandes S, Solé G (2021) A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases. Orphanet J Rare Dis 16: 450. https://doi.org/10.1186/s13023-021-02090-y
    [28] Asadi-Pooya AA, Akbari A, Emami A, et al. (2022) Long COVID syndrome-associated brain fog. J Med Virol 94: 979-984. https://doi.org/10.1002/jmv.27404
    [29] Sun L, Zhao M, Yu XJ, et al. (2013) Cardioprotection by acetylcholine: a novel mechanism via mitochondrial biogenesis and function involving the PGC-1α pathway. J Cell Physiol 228: 1238-1248. https://doi.org/10.1002/jcp.24277
    [30] Moftah MB, Eswayah A (2022) Repurposing of hydroxyurea against COVID-19: a promising immunomodulatory role. Assay Drug Dev Technol 20: 55-62. http://doi.org/10.1089/adt.2021.090
    [31] Que Y, Hu C, Wan K, et al. (2022) Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol 41: 217-230. https://doi.org/10.1080/08830185.2021.1884248
    [32] Cai J, Chen-Goodspeed A, Idowu M (2022) Risk and protective factors for severe COVID-19 infection in a cohort of patients with sickle cell disease. J Investig Med 70: 1243-1246. https://doi.org/10.1136/jim-2021-002196
    [33] Yasara N, Premawardhena A, Mettananda S (2021) A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic. Orphanet J Rare Dis 16: 114. https://doi.org/10.1186/s13023-021-01757-w
  • Reader Comments
  • © 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
AIMS Medical Science
0.4

Metrics

Article views(1685) PDF downloads(232) Cited by(0)

Preview PDF
Download XML
Export Citation
Article outline

Figures and Tables

Tables(1)

Other Articles By Authors

Related pages

Tools

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog